Zio XT ECG Monitoring System vs Reveal LINQ Insertable Cardiac Monitor

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 70/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
Zio XT ECG Monitoring System
by iRhythm Technologies
VS
Reveal LINQ Insertable Cardiac Monitor
by Medtronic

AI Verdict

The Zio XT ECG Monitoring System is a non-invasive, short-term wearable ECG monitor designed for up to 14 days of continuous cardiac monitoring, suitable for initial diagnostic workups. In contrast, the Reveal LINQ Insertable Cardiac Monitor is an implantable device offering long-term (up to 4.5 years) continuous monitoring, ideal for detecting infrequent arrhythmias or for extended surveillance. While both leverage AI for cardiac rhythm analysis, their differing deployment methods and monitoring durations cater to distinct clinical needs.

Choose Zio XT ECG Monitoring System if…

Choose Zio XT if you require a non-invasive, patient-friendly cardiac monitoring solution for up to 14 days to diagnose intermittent arrhythmias. Its wearable, leadless design promotes high patient comfort and compliance, making it ideal for initial diagnostic workups where a short-term, continuous ECG is sufficient to capture symptomatic or asymptomatic events.

View Zio XT ECG Monitoring System →

Choose Reveal LINQ Insertable Cardiac Monitor if…

Choose Reveal LINQ if a patient needs long-term, continuous cardiac monitoring for several years to detect infrequent or elusive arrhythmias, particularly after shorter-term monitoring has been inconclusive. This implantable device is best suited for patients with recurrent unexplained syncope or palpitations, offering prolonged diagnostic yield with advanced AI to minimize false alerts.

View Reveal LINQ Insertable Cardiac Monitor →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature Zio XT ECG Monitoring System Reveal LINQ Insertable Cardiac Monitor
Pricing Contact for pricing Contact vendor
Deployment Cloud-based (AWS EC2 platform), no on-premise hardware required. Implantable device with data transmitted to a cloud-based platform (CareLink™ network) via patient smartphone app or home communicator.
BAA Available Yes AI-estimated Yes AI-estimated
FDA Status Yes AI-estimated Yes AI-estimated
HIPAA Yes AI-estimated Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Zio XT ECG Monitoring System

Tool A, the Zio XT, is a non-invasive, wearable patch that offers superior patient comfort and ease of application for temporary monitoring. Its water-resistant design and lack of wires contribute to high patient compliance and a seamless daily experience, making it highly usable for patients.

Clinical Value

Reveal LINQ Insertable Cardiac Monitor

Tool B, the Reveal LINQ, provides continuous, long-term monitoring for up to 4.5 years, which is critical for detecting infrequent and elusive arrhythmias that short-term monitors might miss. Its AccuRhythmu2122 AI algorithms specifically reduce false alerts, enhancing diagnostic accuracy and clinician efficiency over an extended period.

Pricing & Value

Zio XT ECG Monitoring System

Tool A offers transparent pricing details for both the UK and US markets, allowing healthcare providers to readily assess potential costs and value. In contrast, Tool B requires direct vendor contact for pricing, making initial cost evaluation less straightforward.

Enterprise Readiness

Tie

Both tools are FDA-cleared, HIPAA compliant, and utilize robust cloud-based platforms for data management, demonstrating strong foundational enterprise readiness. While Tool A highlights 'no on-premise hardware required,' both effectively integrate into healthcare workflows through their respective cloud infrastructures.

Innovation

Reveal LINQ Insertable Cardiac Monitor

Tool B demonstrates significant innovation through its long-term implantable design with a 4.5-year battery life, enabling continuous monitoring for highly elusive cardiac events. Its specialized AccuRhythmu2122 AI algorithms for reducing false alerts in an implantable context represent a targeted advancement in diagnostic accuracy for chronic conditions.

Support & Docs

Tie

The provided structured facts do not contain specific information regarding the support services or documentation available for either Tool A or Tool B. Without this crucial comparative data, it is not possible to determine a winner.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature Zio XT ECG Monitoring System Reveal LINQ Insertable Cardiac Monitor
Device Type Wearable single-lead ECG biosensor (Zio biosensor) Insertable Cardiac Monitor (ICM) - Implantable device
Monitoring Duration Up to 14 days of continuous cardiac monitoring Continuous, long-term subcutaneous ECG monitoring (4.5-year battery longevity)
AI Algorithm Proprietary, FDA-cleared deep-learned AI algorithm for ECG data analysis AccuRhythmu2122 AI algorithms for reduced false alerts (AF and Pause)
Patient Data Transmission Cloud-based software platform (ZEUS) for data storage, analysis, and reporting; patient-activated button for symptomatic event logging MyCareLink Heartu2122 mobile app for patient data transmission; MyCareLink Relayu2122 home communicator for data transmission
Key Physical Features Water-resistant design, no external leads or wires MRI compatible (at u2264 3T with no post-insertion waiting), remote programming capabilities

Videos

Demos, reviews, and walkthroughs featuring Zio XT ECG Monitoring System and Reveal LINQ Insertable Cardiac Monitor.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

The Zio XT is a wearable, single-lead ECG biosensor that provides continuous cardiac monitoring for up to 14 days. In contrast, the Reveal LINQ II is an insertable cardiac monitor (ICM) that offers continuous, long-term subcutaneous ECG monitoring with a 4.5-year battery longevity.
The Zio XT utilizes a proprietary, FDA-cleared deep-learned AI algorithm for ECG data analysis and accurate arrhythmia detection. The Reveal LINQ II features AccuRhythmu2122 AI algorithms specifically designed to reduce false alerts for conditions like atrial fibrillation (AF) and pause, enhancing diagnostic yield.
With the Zio XT, patients wear a water-resistant biosensor and can log symptomatic events using a patient-activated button, with data sent to the company for analysis after the wear period. The Reveal LINQ II is an implantable device that transmits data to a cloud-based platform (CareLinku2122 network) via the MyCareLink Heartu2122 mobile app or the MyCareLink Relayu2122 home communicator.
Pricing for the Zio XT is publicly available, with UK costs at u00a3310 per patient and proposed US Medicare rates ranging from approximately $229-$260.35. For the Reveal LINQ II, pricing is typically not publicly disclosed and requires direct consultation with Medtronic sales representatives.
The Zio XT is listed for Cardiology, Emergency Medicine, and Internal Medicine, intended for continuous monitoring for up to 14 days. The Reveal LINQ II is indicated for Cardiology and Pediatrics, offering long-term monitoring for patients with infrequent symptoms requiring ongoing management.

More Comparisons

Assert-IQ vs Rapid Enterprise Platform
AISAP Cardio vs Rapid Enterprise Platform
AngioWaveNet vs Rapid Enterprise Platform
CorVista System with PH Add-On vs Rapid Enterprise Platform

More matchups featuring Zio XT ECG Monitoring System or Reveal LINQ Insertable Cardiac Monitor

Backers

Who funded each tool's parent company.

Zio XT ECG Monitoring System

AI Tool Finder
AI-powered search. Results may not be comprehensive.